title: Tissue specific effects of the beta 2-adrenergic agonist salbutamol on LPS-induced IFN-gamma, IL-10 and TGF-beta responses in vivo.
abstract: Beta2-adrenergic agonists have immunomodulatory effects both in vitro and in vivo. We describe that oral salbutamol (beta-adrenergic agonist) administration has tissue-specific effects on cytokine production induced by intraperitoneal (i.p.) lipopolysaccharide (LPS) administration. Salbutamol reduced LPS-induced IFN-gamma levels at both mucosal and non-mucosal sites. However, salbutamol increased IL-10 levels in the peritoneal cavity, but decreased levels in terminal ileum and lung. Salbutamol did not alter LPS-induced TGF-beta levels in the terminal ileum, but increased levels in liver and peritoneal cavity. Thus, orally administered salbutamol decreases LPS-induced IFN-gamma levels in all tissues tested, but has tissue specific effects on IL-10 and TGF-beta levels.
authors.affiliation: Laboratory for Psychoneuroimmunology, University Medical Center Utrecht, Room KC03.068.0, Lundlaan 6, 3584 EA, Utrecht, The Netherlands.
authors.forename: Niels
authors.initials: N
authors.lastname: Eijkelkamp
authors.forename: Pieter M
authors.initials: PM
authors.lastname: Cobelens
authors.forename: Virginia M
authors.initials: VM
authors.lastname: Sanders
authors.forename: Cobi J
authors.initials: CJ
authors.lastname: Heijnen
authors.forename: Annemieke
authors.initials: A
authors.lastname: Kavelaars
mesh_terms: D000284:Administration, Oral; D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000420:Albuterol / Q000008:administration & dosage*; D000818:Animals; D005260:Female; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D016753:Interleukin-10 / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D007421:Intestine, Small / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008070:Lipopolysaccharides / Q000008:administration & dosage* / Q000037:antagonists & inhibitors; D008099:Liver / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009928:Organ Specificity / Q000187:drug effects / Q000276:immunology; D010533:Peritoneal Lavage; D018343:Receptors, Adrenergic, beta-2 / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000096:biosynthesis*
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D008070:Lipopolysaccharides; D018343:Receptors, Adrenergic, beta-2; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D007371:Interferon-gamma; D000420:Albuterol